Title : Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.

Pub. Date : 2018 Apr

PMID : 29599351






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer. Docetaxel epidermal growth factor receptor Homo sapiens
2 BACKGROUND: Chemotherapy with trastuzumab, pertuzumab and docetaxel (TPD regimen) is now strongly recommended as a treatment option for first-line therapy for advanced human epidermal growth factor receptor (HER)2-positive breast cancer. Docetaxel epidermal growth factor receptor Homo sapiens